Posted on

24 hour trip anyone?

MINDCURE Achieves Key Development Milestone for Novel Ibogaine Program

Tripping on ibogaine can last over 24 hours, and it’s not always pleasant. But the wide range of benefits could make it worthwhile. 

MINDCURE (MCUR) hopes so at least. The company filed a provisional patent for synthetic ibogaine mixtures to treat various central nervous system disorders like:

  • Addiction
  • Traumatic brain injury
  • Anxiety disorders
  • Chronic pain such as migraines and cluster headaches

The company aims to be a global supplier of synthetic ibogaine for research purposes and expects to have supply available by the end of Q2 this year.

PDF of article

‍

Posted on

MINDCURE Announces Strategic Review

MINDCURE Announces Strategic Review

VANCOUVER, BC, Feb. 10, 2022 /PRNewswire/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology for mental health care and research in psychedelics, announced today its Board of Directors has formed a special committee (the “Special Committee”) of independent directors to initiate a review process to explore, review and evaluate a broad range of strategic alternatives.

The Special Committee’s strategic review process will encompass an evaluation of the Company’s current strategic direction, operations, market valuation and capital structure and will consider appropriate alternatives for the Company which may include one or more of the following: continuation as a standalone public company, strategic investor investment, acquisition by or a merger with an industry partner that may involve all or part of our business or assets and any other strategic alternatives that may be identified during our strategic review.

“The Board continues to support the Company’s current strategic priorities. As we recently reported, the Company is in a strong financial position with cash and equivalents of $13.4M and a cash runway of a minimum 12 months as at November 30, 2021.  However, the Board believes that given the current state of capital markets and the evolving landscape for our industry, a broad review of strategic alternatives is entirely appropriate and in the best interest of the Company,” said the Chair of MINDCURE’s Board of Directors, Philip Tapley.

“I am proud of our team and track record of delivering on milestones with focus and drive. I look forward to engaging in this process with the Special Committee while my team pursues our ambitious plan, supported by our strong financial position,” said MINDCURE’s President and CEO Kelsey Ramsden.

The Special Committee is being chaired by Jason Pamer, includes Larissa Chaikowsky, Robert Hill and Philip Tapley, and has appointed Canaccord Genuity Corp. as its financial advisor to support the Special Committee in the strategic review process.

While the strategic review process is ongoing, the Company intends to continue to pursue its core strategic objectives so as to maintain and enhance the value of its current business and operations, including the development and launch of the iSTRYM™ product.

Other than as described in this news release, the Company has not made any decisions related to strategic alternatives at this time and there can be no assurance that the evaluation of strategic alternatives will result in any transaction proceeding or change in strategy. The Company does not intend to comment further unless and until further disclosure is appropriate or necessary.

About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The Company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com.

On Behalf of the Board of Directors
Jason Pamer, Chair of the Special Committee
Phone: 1-888-593-8995
Email: specialcommittee@mindcure.com

The Canadian Securities Exchange (“CSE”) has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information
Certain information regarding MINDCURE and its business presented in this news release may constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases.

Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the considerations and outcome of the strategic review; COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; no unanticipated expenses, costs or detrimental consequences of the strategic review process will arise; the continuation of the Company’s core strategic objectives, including the development and launch of the iSTRYM product, so as to preserve and enhance the value of the Company’s current business and operations; and the expected cash runway of the Company’s business.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information inherently entails known and unknown risks and uncertainties about the future and actual results and involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed.

Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

‍

Posted on

MINDCURE Hires Dr. Clare Purvis from Headspace to the position of Chief Product Officer to Advance Mental Health Digital Therapeutics Platform

MINDCURE Hires Dr. Clare Purvis from Headspace to the position of Chief Product Officer to Advance Mental Health Digital Therapeutics Platform


VANCOUVER, BC, Feb. 3, 2022 – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology for mental health care and research in psychedelics, announced today the hiring of Dr. Clare Purvis, formerly Headspace Inc.’s Vice President of Clinical Product and Content Development, for the Company’s newly created role of Chief Product Officer to focus on building and expanding the reach of iSTRYM, its digital therapeutics platform.

“As care becomes more personalized, the need has never been greater for high quality, scalable digital therapeutics in the mental healthcare space, and I’m excited to join the MINDCURE team at the forefront of the progress being made,” said Dr. Purvis adding, “iSTRYM has proven itself in a fast-growing market and I believe it has the potential to become a dominating force as the product of choice for clinics utilizing technology-assisted therapies.”

While working at Headspace, Dr. Purvis was on the Executive Leadership Team responsible for clinical and scientific strategy, helping to set the company’s overall strategy and overseeing new product development in mental and behavioral health starting in 2019.  She currently serves as a Clinical Advisory Board member at Brightline, which provides a technology-driven approach to pediatric behavioral health.

“It’s a pivotal and proud moment in the trajectory of MINDCURE as we welcome Dr. Purvis to the team. Clare’s experience, expertise and reputation as a thought leader and science-backed leader in the fast-growing digital mental health space will be an invaluable addition to MINDCURE’s growth in the mental healthcare industry,” said MINDCURE’s President and CEO Kelsey Ramsden. “As MINDCURE pushes forward to make Mental WealthTM a reality for more people, Clare will be leading the charge on delivering a truly transformational and high value experience for both therapists, patients and ultimately, payers,” Ramsden added.

MINDCURE’s product solution, iSTRYM, is expanding to cover a broader market which will include clinics that operate in both psychedelic-assisted psychotherapy and general psychotherapy and psychiatry. It is for this purpose that MINDCURE is introducing the role of Chief Product Officer to deliver the above initiatives. After successfully creating its initial product as Chief Technology Officer, Geoff Belair will spearhead the migration of our technology team to an engineering division, with focus on data strategy and build-out of MINDCURE’s AI models supporting the product. In his new role as Vice President of Engineering, Mr. Belair will report to the CPO and will be working closely with Dr. Purvis to ensure success as MINDCURE drives to commercialization.

“I would like to thank Mr. Belair for his visionary architecture of the platform and look forward to his continued service in this new role,” said MINDCURE’s President and CEO Kelsey Ramsden.

Dr. Purvis is a licensed clinical psychologist and she received her Doctorate in Psychology from the PGSP-Stanford Consortium where she trained in the Stanford Department of Psychiatry and Behavioral Sciences.  She serves as an Affiliated Scholar at Stanford University’s Clinical Excellence Research Center, where she provides consultation on the use of technology to make great healthcare more affordable.  

MINDCURE is also announcing that Daniel Herrera, current Vice President, Growth and Strategic Partnerships, has been promoted to the role of Chief Growth Officer as result of his exceptional performance to date. His continued work in this position will drive MINDCURE forward as we near commercialization of iSTRYM and plan for significant growth in the coming years.

ISTRYM is currently partnered with 20 clinics in North America during its closed beta roll out.  Full commercialization of the platform is expected in Q2 of 2022.  Mental healthcare therapists and psychiatrists wishing to get access to the platform this year are currently being welcomed and onboarded in priority sequence.

About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on LinkedIn, Facebook, Twitter, and Instagram.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information
Certain information presented in this news release may constitute “forward-looking information” within the meaning of applicable securities laws regarding MINDCURE and its business. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases.

Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; the Company will develop its products as expected and that they will attain the outcomes anticipated; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that strategic partnerships entered by the Company will create the opportunities and outcomes anticipated; that MINDCURE will advance wellness worldwide; and that HIPAA compliance certification will have a positive impact on the commercial deployment of iSTRYM.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information inherently entails known and unknown risks and uncertainties about the future and actual results and involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed.

Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

Posted on

MINDCURE Announces Financial Results for the Second Quarter of Fiscal 2022

MINDCURE Announces Financial Results for the Second Quarter of Fiscal 2022

VANCOUVER, BC, Jan. 25, 2022 – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research for psychedelics, today announced its financial results and operational highlights for the three and six months ended November 30, 2021. All amounts are stated in Canadian dollars unless otherwise indicated.  

Fiscal Q2 2022 Business Highlights

  • Commenced trading on the OTCQX Best Market on September 30, 2021, the highest tier of OTC Markets Group, under the ticker symbol “MCURF”.
  • Closed an exclusive data licensing agreement with ATMA Journey Centers Inc., a pioneer in the psychedelic therapy industry, and was granted exclusive access to ATMA data from patients using iSTRYM, the Company’s digital therapeutics technology. The data will be leveraged to further optimize iSTRYM and position it as the industry’s distribution network for science-based, evidence-backed protocols and AI data systems.
  • Signed a letter of intent with Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF) to be a distributor of its ketamine-assisted psychotherapy for Alcohol Use Disorder protocol in the US and Canada.
  • Partnered with 20 ketamine clinics in nine states in the U.S. and three provinces in Canada to release the minimum viable product version of iSTRYM, with plans to further expand in 2022.
  • Introduced the “Desire Project”, a clinical research program focused on the treatment of female hypoactive sexual desire disorder with MDMA-assisted psychotherapy. This is the first psychedelics-based treatment program targeted at addressing Hypoactive Sexual Desire Disorder.
  • Joined the Digital Therapeutics Alliance, a non-profit association of industry leaders with a mission to drive awareness and adoption of digital therapies.
  • Advanced preparations to ship ibogaine drug material to its pre-clinical research partner.
  • Included in the AdvisorShares Psychedelics ETF, which trades on the NYSE Arca under the ticker symbol “PSIL”.

Recent Events

  • The Company and its digital therapeutics technology, iSTRYM, were certified as Health Insurance Portability and Accountability Act (HIPAA) compliant, making a further step toward commercial deployment in the second quarter of 2022.
  • Appointed Dr. Doron Sagman, MD, FRCPC, as the Company’s new Chief Medical Officer (“CMO”). Dr. Joel Raskin who was acting CMO will transition into an advisory role.

“During the second quarter of fiscal 2022, we achieved several key milestones across our digital technology and research projects, further proving our ability to successfully execute against our strategic growth strategy,” said Kelsey Ramsden, President & CEO of MINDCURE. “We are continuing to build out our team with key industry leaders, positioning the Company to develop innovative treatments that promote healing and improve mental health.”

Financial Highlights

  • Net loss for the three months ended November 30, 2021 was $2.95 million, comprised of cash operating expenses of $2.9 million, non-cash operating expenses of $0.3 million and an unrealized gain of $0.2 million.
  • Cash and cash equivalents totalled $13.4 million as of November 30, 2021.

A copy of the Company’s financial statements for the three and six months ended November 30, 2021 and the related management’s discussion and analysis are available under the Company’s profile on SEDAR at www.sedar.com.

In other news, the Company also announces it has granted a total of 110,000 stock options to certain employees pursuant to the terms the Company’s long term incentive plan (“Plan”). The stock options are exercisable at a price of $0.21 per share, and are subject to the terms of the Plan.

About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on Facebook, Twitter, and Instagram.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information
Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that iSTRYM will be developed, optimized and operate as contemplated within the psychedelics industry; that the Company will be effective in obtaining the patents applied for synthesizing ibogaine, or synthesizing ibogaine, or developing synthesized ibogaine for research, medical or commercial use; that MINDCURE will advance wellness worldwide; that iSTRYM will be brought to commercial deployment in the near term or otherwise or that it will reduce symptoms, improve quality of life, or support transformation and healing, or that the deployment may not occur at the scale or within the time frame contemplated.

Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed.

Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

For further information: MINDCURE Investor Relations, Daniel Kim, VP Investor Relations, dkim@mindcure.com, 1-888-593-8995

Posted on

MINDCURE to Participate in the H.C. Wainwright Bioconnect Conference in January 2022

MINDCURE to Participate in the H.C. Wainwright Bioconnect Conference in January 2022

VANCOUVER, BC, Jan. 6, 2022 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research for psychedelics, today announced that President & Chief Executive Officer, Kelsey Ramsden, will present virtually at the H.C. Wainwright Bioconnect Conference taking place on January 10-13, 2022.

A webcast of MINDCURE’s presentation will be available on-demand from Monday, January 10th at 7:00a.m. ET via this link: https://journey.ct.events/view/0f297ecc-702f-45d2-9952-45218d7559f1. A recording of the webcast can be viewed through the above link for 90 days.

To schedule a one-on-one meeting with MINDCURE’s management team, please contact KCSA Strategic Communications at mindcureIR@kcsa.com.

The Company also announces it has granted a total of 350,000 stock options to certain employees and consultants pursuant to the terms of the Company’s long term incentive plan (“Plan”). The stock options are exercisable: 250,000 at a price of $0.195 per share and 100,000 at a price of $0.215 per share, and are subject to the terms of the Plan.

About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on LinkedIn, Facebook, Twitter, and Instagram.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information
Certain information presented in this news release may constitute “forward-looking information” within the meaning of applicable securities laws regarding MINDCURE and its business. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors could cause actual results to differ materially from the Company’s expectations, including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

For further information: MINDCURE Investor Relations: investors@mindcure.com, 1-888-593-8995; Media Inquiries: Annie Graf / Kristin Cwalinski, KCSA Strategic Communications, mindcure@kcsa.com

Posted on

MINDCURE Appoints Dr. Doron Sagman as Chief Medical Officer

MINDCURE Appoints Dr. Doron Sagman as Chief Medical Officer

VANCOUVER, BC, Dec. 14, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research for psychedelics, announces the appointment of Doron Sagman, MD, FRCPC, as the Company’s new Chief Medical Officer (“CMO”). Dr. Joel Raskin who was acting CMO will transition into an advisory role for MINDCURE.

As CMO, Dr. Sagman will play a vital role in furthering MINDCURE’S mission to reinvent the mental health care model for patients and practitioners, along with advancing psychedelic-assisted therapy into common and accepted care.  A trained psychiatrist with an expertise in mood and anxiety disorders, as well as an experienced leader in pharmaceutical drug development and clinical trials, Dr. Sagman brings three decades of clinical and research and regulatory experience to MINDCURE.

“Dr. Sagman’s distinguished career in both mental health and the pharmaceutical industries will enable him to lead the development of innovative therapies to potentially treat a range of mental health conditions,” said Kelsey Ramsden, President & CEO of MINDCURE.  “His proven experience as a leader who has built and led diverse teams, as well as his deep understanding of the drug research and development process, will be critical as MINDCURE advances on our path to research digital therapeutic and neuro-supportive solutions,” Ramsden added.

Throughout the span of his 18-year career in the pharmaceutical industry, Dr. Sagman held leadership positions across medical research, clinical development, regulatory affairs and medical affairs.  Most recently, Dr. Sagman held the position of Senior Medical Director/Vice-President, R&D and Medical Affairs at Eli Lilly Canada, leading the medical affairs, clinical and regulatory affairs divisions across a broad therapeutic span, including neuroscience, immunology, oncology, and diabetes.

On his appointment, Dr Sagman said, “We are entering a pivotal and historical phase of medical discovery for patients who suffer from mental health disorders. I am delighted to join MINDCURE’s leadership team and work to advance innovative solutions to best meet unmet mental health needs.”

On Dr. Sagman’s appointment, Dr. Joel Raskin added, “Dr. Sagman’s experience in managing clinical operations, regulatory, quality, people and all aspects of research in Canada makes him the perfect candidate to lead MINDCURE’s research and brings a competitive edge as the Company grows.”

In addition to receiving his medical degree from University of Calgary, Dr. Sagman completed his psychiatric residency at the University of Toronto. He is a Fellow of the Royal College of Physicians & Surgeons of Canada (FRCPC) and an Adjunct Clinical Lecturer in the Department of Psychiatry at the University of Toronto, as well as being a staff psychiatrist at the Michael Garron Hospital in Toronto.

About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on LinkedIn, Facebook, Twitter, and Instagram.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information
Certain information presented in this news release may constitute “forward-looking information” within the meaning of applicable securities laws regarding MINDCURE and its business. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors could cause actual results to differ materially from the Company’s expectations, including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

Posted on

MINDCURE to Participate in Upcoming Conferences in December 2021

MINDCURE to Participate in Upcoming Conferences in December 2021

VANCOUVER, BC, Dec. 2, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research for psychedelics, today announced that President & Chief Executive Officer, Kelsey Ramsden, will present virtually at H.C. Wainwright’s 2nd Annual Psychedelics Conference, the Psychedelics Now Virtual Conference, the #CanndoraConnect: Women in Psychedelics Conference and the Life Sciences Investor Forum in December.

H.C. Wainwright’s 2nd Annual Psychedelics Conference
DATE: December 6th, 2021
TIME: 7:00a.m. ET
LINK: https://journey.ct.events/view/87e7f660-cb8f-40d3-ad91-8a3cd7a10f75

A webcast of MINDCURE’s presentation will be available on-demand from Monday, December 6th at 7:00a.m. ET. A recording of the presentation will be accessible on MINDCURE’s investor relations website via the above link for 90 days.

Psychedelics Now Virtual Conference
DATE: December 8th, 2021
TIME: 1:00p.m. ET
LINK: https://www.airmeet.com/e/0eaf96e0-47f9-11ec-90a4-bb052aa99b8c

Ms. Ramsden will participate in the ‘Road to Monetization’ webcast panel at the Psychedelics Now Virtual Conference. Please register to view the panel via the link above.

#CanndoraConnect: Women in Psychedelics Conference
DATE: December 8th, 2021
TIME: 3:05p.m. ET
LINK: https://www.eventbrite.ca/e/canndoraconnect-women-in-psychedelics-tickets-162722149329

Ms. Ramsden will also participate in the ‘Exploring Career Opportunities in Psychedelics’ virtual panel at the #CanndoraConnect: Women in Psychedelics Conference. Please register via the link above to view the panel.

Life Sciences Investor Forum
DATE: December 16th, 2021
TIME: 11:30a.m. ET
LINK: https://bit.ly/3cIf2X6

Ms. Ramsden will present virtually at the Life Sciences Investor Forum. An archived webcast will also be made available after the event through the above link.

For more information on the conferences or to schedule a one-on-one meeting with MINDCURE’s management team, please contact KCSA Strategic Communications at mindcureIR@kcsa.com.

The Company also announces it has granted a total of 10,000 stock options to certain employees pursuant to the terms the Company’s long term incentive plan (“Plan”). The stock options are exercisable at a price of $0.29 per share, and are subject to the terms of the Plan.

About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on LinkedIn, Facebook, Twitter, and Instagram.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information
Certain information presented in this news release may constitute “forward-looking information” within the meaning of applicable securities laws regarding MINDCURE and its business. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors could cause actual results to differ materially from the Company’s expectations, including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Mind Cure Health Inc.

For further information:

MINDCURE Investor Relations: investors@mindcure.com, 1-888-593-8995;

Media Inquiries: Annie Graf, Kristin Cwalinski, KCSA Strategic Communications, mindcure@kcsa.com

Posted on

MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol for Alcohol Use Disorder into Clinics Across United States and Canada through iSTRYM, MINDCURE’s Digital Therapeutics Platform

MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol for Alcohol Use Disorder into Clinics Across United States and Canada through iSTRYM, MINDCURE’s Digital Therapeutics Platform

VANCOUVER, BC, October 28, 2021 – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research for psychedelics, is pleased to announce the signing of a non-binding letter of intent (“LOI”) with Awakn Life Sciences (NEO: AWKN)(OTCQB: AWKNF) (“Awakn”), a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicine to better treat Addiction.

The Company will enter into an agreement with Awakn to be a distributor of its ketamine-assisted psychotherapy for Alcohol Use Disorder (AUD) protocol in the US and Canada. Awakn’s protocol will be distributed through iSTRYM, MINDCURE’s digital therapeutics platform.

MINDCURE released the minimum viable product (MVP) version of iSTRYM into partner clinics across North America in August and will begin full commercial deployment to all partner clinics in Q1 of 2022. The company forecasts 75 partner clinics in Canada and the US deploying iSTRYM upon commercialization. Further deployment anticipates 150 clinics across Canada, the US, the UK, and Europe by Q4 2022.

iSTRYM provides a digital distribution network of science-based protocols developed by MINDCURE’s clinical partners, companies, academic institutions, and other healthcare providers directly to therapists. The Company is already partnering with ketamine-assisted psychotherapy clinics in nine states in the US and two provinces in Canada with plans to expand to the broader mental health market in 2022. The distribution component of iSTRYM unlocks another revenue line for MINDCURE, in addition to clinic and patient level revenues from the platform.

“Awakn’s goal is to fully integrate evidence-backed psychedelic-assisted psychotherapy into mainstream healthcare to better treat addiction. We’re currently building the UK and Europe’s leading chain of medical psychedelic clinics with a focus on treating addiction and other mental health conditions,” said Anthony Tennyson, CEO of Awakn Life Sciences. “We are extremely pleased that we now also have a partnership with MINDCURE to distribute our ketamine-assisted psychotherapy for Alcohol Use Disorder protocol through their iSTRYM platform in the US and Canada.”

Awakn acquired the licensing rights from the University of Exeter for a ketamine-assisted psychotherapy treatment for AUD, which has been validated in a completed Phase II a/b trial. Awakn’s license to use and deliver the ‘Ketamine in the Reduction of Alcoholic Relapse’ (KARE) psychotherapy treatment will be deployed in each of Awakn’s clinics in the UK and Europe and will be led by a consultant psychiatrist. Awakn’s Team includes world leading scientific, research and clinical experts in the treatment addiction, led by Professor David Nutt, who serves as Awakn’s Chief Research Officer and Chair of both the Scientific Advisory Boards (Preclinical and Clinical). The KARE protocol will be distributed by MINDCURE in its digital therapeutic platform across its growing network of clinical partners in the US and Canada.

“Improving mental health is a global challenge and we’re building iSTRYM to be an innovative global solution,” said Kelsey Ramsden, President & CEO, MINDCURE. “This is our first of many overseas partnerships with industry leaders who are developing scientifically rigorous psychedelics protocols and drugs whereby our technology provides a natural distribution partner to support both patients and therapists.”

About Awakn

Awakn Life Sciences (“Awakn”) is a biotechnology company with clinical operations, researching, developing, and delivering psychedelic medicine to better treat Addiction. Awakn’s team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat Addiction. Awakn will also deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licencing partnerships globally. Learn more at awaknlifesciences.com.

About MINDCURE

Mind Cure Health (“MINDCURE”) is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on LinkedIn, Facebook, Twitter, and Instagram.

On Behalf of the Board of Directors

Kelsey Ramsden, President & CEO

Phone: 1-888-593-8995

Forward-Looking Information

Certain information presented in this news release may constitute “forward-looking information” within the meaning of applicable securities laws regarding MINDCURE and its business. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases.

Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; the Company will develop its products as expected and that they will attain the outcomes anticipated; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that strategic partnerships entered by the Company will create the opportunities and outcomes anticipated; that MINDCURE will advance wellness worldwide; that trading on the OTCQX will attract additional investment and provide additional liquidity for shareholders

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information inherently entails known and unknown risks and uncertainties about the future and actual results and involves significant risks and

uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: iSTRYM distributing Awakn’s ketamine-assisted psychotherapy for Alcohol Use Disorder protocol in the US and Canada. Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed.

Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

For further information:

MINDCURE Investor Relations

investors@mindcure.com

1-888-593-8995

Media Inquiries

Annie Graf / Kristin Cwalinski

KCSA Strategic Communications

mindcure@kcsa.com

Posted on

MINDCURE Announces Participation at Upcoming Events in November 2021

MINDCURE Announces Participation at Upcoming Events in November 2021

VANCOUVER, BC, October 27, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research in psychedelics, today announced that Kelsey Ramsden, President & CEO of MINDCURE, will participate in two upcoming events in November 2021:  

  • Wonderland Miami to be held in-person on November 8-9. MINDCURE will participate as a Silver Sponsor at the largest in-person conference focusing on the psychedelic medicine industry. Ms. Ramsden will participate in a number of panel presentations during the conference.  The event is organized by Microdose Psychedelic Insights (“Microdose”), a portfolio company of Origin Therapeutics. For panel information or to attend, please visit the event website here.
    ‍
  • Mind Medicine Australia (“MMA”) will host an International Summit on Psychedelic Therapies for Mental Illness, to be held virtually from Australia on November 19-20. MINDCURE is a Supporting Partner of MMA, and Ms. Ramsden will participate in a panel presentation called “Creating the Future: What the Psychedelic Industry Will Look Like 5 Years Out”. To attend, please register here.

For more information about the conferences, or to schedule a one-on-one meeting with MINDCURE management, please contact KCSA Strategic Communications at MindCure@kcsa.com.

About Mind Cure Health Inc.

MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on LinkedIn, Facebook, Twitter, and Instagram.

On Behalf of the Board of Directors

Kelsey Ramsden, President & CEO

Phone: 1-888-593-8995 

Forward-Looking Information

Certain information presented in this news release may constitute “forward-looking information” within the meaning of applicable securities laws regarding MINDCURE and its business. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases.

Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; the Company will develop its products as expected and that they will attain the outcomes anticipated; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that strategic partnerships entered by the Company will create the opportunities and outcomes anticipated; that MINDCURE will advance wellness worldwide; and that trading on the OTCQX will attract additional investment and provide additional liquidity for shareholders.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information inherently entails known and unknown risks and uncertainties about the future and actual results and involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed.

Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

TheCSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

For further information:

‍MINDCURE Investor Relations

investors@mindcure.com

1-888-593-8995

‍Media Inquiries

Annie Graf / KristinCwalinski

KCSA StrategicCommunications

mindcure@kcsa.com

Posted on

MINDCURE Announces Financial Results for the First Quarter of Fiscal 2022

MINDCURE Announces Financial Results for the First Quarter of Fiscal 2022

VANCOUVER, BC, Oct. 26, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research for psychedelics, today announced its financial results for the three months ended August 31, 2021.  All amounts are stated in Canadian dollars unless otherwise indicated.  

Q1 Fiscal 2022 Business Highlights

  • Released the minimum viable product version of iSTRYM, the Company’s digital therapeutics (DTx) platform, into partner clinics across North America;
  • Completed full chemical synthesis of ibogaine, launched the second stage of manufacturing, and filed two provisional patent applications;
  • Developed proprietary ketamine-enhanced psychotherapy protocols for treatment of pain and depression;
  • Completed a strategic equity investment in Awakn Life Sciences Inc.;
  • Signed exclusive digital clinical data licensing agreement with ATMA Journey Centers; and
  • Subsequent to quarter end, introduced the “Desire Project”, a clinical research program focused on the treatment of female hypoactive sexual desire disorder with MDMA-assisted psychotherapy.

“Q1 was a significant quarter for MINDCURE, as we achieved several key milestones including the launch of the minimum viable product of iSTRYM, our digital therapeutics platform,” stated Kelsey Ramsden, President & CEO of MINDCURE.  “We closed the quarter with a strong cash position and have a solid pipeline of catalysts over the next few months. I look forward to sharing more updates as we continue to prepare iSTRYM for commercial deployment, progress in the manufacturing of ibogaine, and advance our Desire Project.”

Q1 Fiscal 2022 Financial Highlights

  • Cash and cash equivalents totalled $15.6 million as at August 31, 2021;
  • Net loss for the three months ended August 31, 2021 was $2.8 million, comprised of non-cash operating expenses of $0.3 million, an inventory write down of $0.2 million; an unrealized investment loss of $0.1 million, and cash operating expenses of $2.2 million.

A copy of the Company’s financial statements for the three months ended August 31, 2021, and the related management’s discussion and analysis are available under the Company’s profile on SEDAR at www.sedar.com.

In other news, the Company announces it has granted a total of 70,000 stock options to certain employees pursuant to the terms the Company’s long term incentive plan (“Plan”). The stock options are exercisable at prices between $0.295 per share and $0.325 per share and are subject to the terms of the Plan. The Company further announces it has issued 108,224 common shares to a consultant at agreed-upon prices between $0.31 per share and $0.60 per share.

About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com and follow us on LinkedIn, Facebook, Twitter, and Instagram.

On Behalf of the Board of Directors

Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information
Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that iSTRYM will be developed, optimized and operate as contemplated within the psychedelics industry; that the Company will be effective in obtaining the patents applied for synthesizing ibogaine, or synthesizing ibogaine, or developing synthesized ibogaine for research, medical or commercial use; that MINDCURE will advance wellness worldwide; that iSTRYM will be brought to commercial deployment in the near term or otherwise or that it will reduce symptoms, improve quality of life, or support transformation and healing, or that the deployment may not occur at the scale or within the time frame contemplated.

Although MINDCURE has attempted to identify important factors that could cause actual results,  performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed.

Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

For further information: MINDCURE Investor Relations, investors@mindcure.com, 1-888-593-8995; Media Inquiries, Annie Graf / Kristin Cwalinski, KCSA Strategic Communications, mindcure@kcsa.com